Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis

Ana-Maria Orbai; Joshua Weitz; Evan L Siegel; Stefan Siebert; Laura J Savage; Sibel Z Aydin; Jolanda J Luime; Ori Elkayam; Barbara Neerinckx; Slavo Urbancek; Kurt de Vlam; Christopher T Ritchlin; GRAPPA Enthesitis Working Group

doi:10.3899/jrheum.140878

Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis

J Rheumatol. 2014 Nov;41(11):2290-4. doi: 10.3899/jrheum.140878.

Affiliations

¹ From Johns Hopkins Arthritis Center, Baltimore, Maryland; Dermatology Associates of Rochester, Rochester, New York; Arthritis and Rheumatism Associates, Rockville, Maryland, USA; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, Koc University, Faculty of Medicine, Istanbul, Turkey; Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Rheumatology, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; University Hospital Leuven, Leuven, Belgium; Department of Dermatology, F.D. Roosevelt Hospital, Banska Bystrica, Slovakia; and Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.A.M. Orbai, MD, MHS, Johns Hopkins Arthritis Center; J. Weitz, MD, Dermatology Associates of Rochester; E.L. Siegel, MD, Arthritis and Rheumatism Associates; S. Siebert, MD, Institute of Infection, Immunity and Inflammation, University of Glasgow; L.J. Savage, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S.Z. Aydin, Department of Rheumatology, Koc University Faculty of Medicine; J.J. Luime, PhD, Department of Rheumatology, Erasmus Medical Center; O. Elkayam, MD, Department of Rheumatology, Tel Aviv Medical Center and Sackler Faculty of Medicine; B. Neerinckx, MD, University Hospital Leuven; S. Urbancek, MD, PhD, Department of Dermatology, F.D. Roosevelt Hospital; K. de Vlam, MD, PhD, University Hospital Leuven; C.T. Ritchlin, MD, MPH, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center. aorbai1@jhmi.edu.
² From Johns Hopkins Arthritis Center, Baltimore, Maryland; Dermatology Associates of Rochester, Rochester, New York; Arthritis and Rheumatism Associates, Rockville, Maryland, USA; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Department of Rheumatology, Koc University, Faculty of Medicine, Istanbul, Turkey; Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Rheumatology, Tel Aviv Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; University Hospital Leuven, Leuven, Belgium; Department of Dermatology, F.D. Roosevelt Hospital, Banska Bystrica, Slovakia; and Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center, Rochester, New York, USA.A.M. Orbai, MD, MHS, Johns Hopkins Arthritis Center; J. Weitz, MD, Dermatology Associates of Rochester; E.L. Siegel, MD, Arthritis and Rheumatism Associates; S. Siebert, MD, Institute of Infection, Immunity and Inflammation, University of Glasgow; L.J. Savage, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; S.Z. Aydin, Department of Rheumatology, Koc University Faculty of Medicine; J.J. Luime, PhD, Department of Rheumatology, Erasmus Medical Center; O. Elkayam, MD, Department of Rheumatology, Tel Aviv Medical Center and Sackler Faculty of Medicine; B. Neerinckx, MD, University Hospital Leuven; S. Urbancek, MD, PhD, Department of Dermatology, F.D. Roosevelt Hospital; K. de Vlam, MD, PhD, University Hospital Leuven; C.T. Ritchlin, MD, MPH, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical Center.

PMID: 25362713
DOI: 10.3899/jrheum.140878

Abstract

Enthesitis is a characteristic feature of psoriatic arthritis (PsA) and is important in disease pathogenesis and classification. Use of clinical outcome measures for enthesitis is heterogeneous, and only 1 measure has been specifically developed and validated in PsA. Ultrasound and magnetic resonance imaging assessments of enthesitis may have advantages over clinical examination but are insufficiently studied. As part of an update of treatment recommendations by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), we performed a systematic literature review and identified randomized controlled trials with enthesitis outcomes in PsA. For each treatment agent we calculated treatment effect sizes (where applicable) and graded the level of evidence.

Keywords: ENTHESITIS; ENTHESOPATHY; OUTCOME MEASURES; PSORIATIC ARTHRITIS; TREATMENT.

Publication types

Review
Systematic Review

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antirheumatic Agents / administration & dosage*
Arthritis, Psoriatic / diagnosis
Arthritis, Psoriatic / drug therapy*
Biological Products / therapeutic use
Female
Humans
Joint Capsule / drug effects
Joint Capsule / physiopathology
Ligaments, Articular / drug effects
Ligaments, Articular / physiopathology
Male
Practice Guidelines as Topic*
Prognosis
Randomized Controlled Trials as Topic
Rheumatic Diseases / diagnosis*
Rheumatic Diseases / drug therapy*
Risk Assessment
Severity of Illness Index
Societies, Medical / standards
Tendinopathy / drug therapy
Tendinopathy / physiopathology
Treatment Outcome

Substances

Adrenal Cortex Hormones
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Biological Products

Grants and funding

MR/K006525/1/MRC_/Medical Research Council/United Kingdom